Finprostat

Finprostat may be available in the countries listed below.

Ingredient matches for Finprostat

Finasteride

Finasteride is reported as an ingredient of Finprostat in the following countries:

• Argentina

International Drug Name Search

Naproxeno Genfar

Naproxeno Genfar may be available in the countries listed below.

Ingredient matches for Naproxeno Genfar

Naproxen

Naproxen is reported as an ingredient of Naproxeno Genfar in the following countries:

• Colombia


• Ecuador


• Peru

International Drug Name Search

Nitroprusiato de Sodio Ecar

Nitroprusiato de Sodio Ecar may be available in the countries listed below.

Ingredient matches for Nitroprusiato de Sodio Ecar

Nitroprusside

Sodium Nitroprusside is reported as an ingredient of Nitroprusiato de Sodio Ecar in the following countries:

• Colombia

International Drug Name Search

Povisept

Povisept may be available in the countries listed below.

Ingredient matches for Povisept

Povidone Iodine

Povidone-Iodine is reported as an ingredient of Povisept in the following countries:

• Yemen

International Drug Name Search

Bidanzen

Bidanzen may be available in the countries listed below.

Ingredient matches for Bidanzen

Serrapeptase

Serrapeptase is reported as an ingredient of Bidanzen in the following countries:

• India

International Drug Name Search

Tralodie

Tralodie may be available in the countries listed below.

Ingredient matches for Tralodie

Tramadol

Tramadol hydrochloride (a derivative of Tramadol) is reported as an ingredient of Tralodie in the following countries:

• Italy

International Drug Name Search

Flucess

Flucess may be available in the countries listed below.

Ingredient matches for Flucess

Fluconazole

Fluconazole is reported as an ingredient of Flucess in the following countries:

• Bangladesh


• Costa Rica


• Dominican Republic


• El Salvador


• Guatemala


• Nicaragua


• Panama

International Drug Name Search

Acido Acetilsalicilico Afom

Acido Acetilsalicilico Afom may be available in the countries listed below.

Ingredient matches for Acido Acetilsalicilico Afom

Aspirin

Acetylsalicylic Acid is reported as an ingredient of Acido Acetilsalicilico Afom in the following countries:

• Italy

International Drug Name Search

Timkent

Timkent may be available in the countries listed below.

Ingredient matches for Timkent

Epinastine

Epinastine hydrochloride (a derivative of Epinastine) is reported as an ingredient of Timkent in the following countries:

• Japan

International Drug Name Search

Vitazink

Vitazink may be available in the countries listed below.

Ingredient matches for Vitazink

Zinc Sulfate

Zinc Sulfate is reported as an ingredient of Vitazink in the following countries:

• Germany

International Drug Name Search

Defendare

Defendare may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Defendare

Permethrin

Permethrin is reported as an ingredient of Defendare in the following countries:

• Portugal

International Drug Name Search

Magnegon

Magnegon may be available in the countries listed below.

Ingredient matches for Magnegon

Magnesium Citrate

Magnesium Citrate is reported as an ingredient of Magnegon in the following countries:

• Switzerland

Magnesium Lactate

Magnesium Lactate dihydrate (a derivative of Magnesium Lactate) is reported as an ingredient of Magnegon in the following countries:

• Switzerland

International Drug Name Search

Gentamicina Hexal

Gentamicina Hexal may be available in the countries listed below.

Ingredient matches for Gentamicina Hexal

Gentamicin

Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Gentamicina Hexal in the following countries:

• Italy

International Drug Name Search

Glibenclamide Sandoz

Glibenclamide Sandoz may be available in the countries listed below.

Ingredient matches for Glibenclamide Sandoz

Glibenclamide

Glibenclamide is reported as an ingredient of Glibenclamide Sandoz in the following countries:

• France


• Netherlands

International Drug Name Search

SPMC Prednisolone

SPMC Prednisolone may be available in the countries listed below.

Ingredient matches for SPMC Prednisolone

Prednisolone

Prednisolone is reported as an ingredient of SPMC Prednisolone in the following countries:

• Sri Lanka

International Drug Name Search

Dulcolax NP

Dulcolax NP may be available in the countries listed below.

Ingredient matches for Dulcolax NP

Sodium Picosulfate

Sodium Picosulfate monohydrate (a derivative of Sodium Picosulfate) is reported as an ingredient of Dulcolax NP in the following countries:

• Germany

International Drug Name Search

Kohletabletten Hänseler

Kohletabletten Hänseler may be available in the countries listed below.

Ingredient matches for Kohletabletten Hänseler

Charcoal

Charcoal, Activated is reported as an ingredient of Kohletabletten Hänseler in the following countries:

• Switzerland

International Drug Name Search

Sulfintestin Neomicina

Sulfintestin Neomicina may be available in the countries listed below.

Ingredient matches for Sulfintestin Neomicina

Dihydrostreptomycin

Dihydrostreptomycin sulfate (a derivative of Dihydrostreptomycin) is reported as an ingredient of Sulfintestin Neomicina in the following countries:

• Spain

Formosulfathiazole

Formosulfathiazole is reported as an ingredient of Sulfintestin Neomicina in the following countries:

• Spain

Neomycin

Neomycin sulfate (a derivative of Neomycin) is reported as an ingredient of Sulfintestin Neomicina in the following countries:

• Spain

International Drug Name Search

Minirin

Minirin is a brand name of desmopressin, approved by the FDA in the following formulation(s):

MINIRIN (desmopressin acetate - spray, metered; nasal)

• 
  Manufacturer: FERRING
  
  Approval date: September 16, 2002
  
  Strength(s): 0.01MG/SPRAY ^[RLD][AB]

Has a generic version of Minirin been approved?

Yes. The following products are equivalent to Minirin:

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) (desmopressin acetate spray, metered; nasal)

• 
  Manufacturer: APOTEX INC
  
  Approval date: January 27, 2005
  
  Strength(s): 0.01MG/SPRAY ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Minirin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Minirin.

See also...

• Minirin Spray Consumer Information (Wolters Kluwer)
• Minirin Advanced Consumer Information (Micromedex)
• Desmopressin Consumer Information (Wolters Kluwer)
• Desmopressin Solution Consumer Information (Wolters Kluwer)
• Desmopressin Spray Consumer Information (Wolters Kluwer)
• Desmopressin Tube Consumer Information (Wolters Kluwer)
• Desmopressin Consumer Information (Cerner Multum)
• Desmopressin injection Consumer Information (Cerner Multum)
• Desmopressin nasal Consumer Information (Cerner Multum)
• Desmopressin Nasal, Oral, Injection Advanced Consumer Information (Micromedex)
• Desmopressin Acetate AHFS DI Monographs (ASHP)

Furedan

Furedan may be available in the countries listed below.

Ingredient matches for Furedan

Nitrofurantoin

Nitrofurantoin is reported as an ingredient of Furedan in the following countries:

• Italy

International Drug Name Search

Metoprolol Heumann

Metoprolol Heumann may be available in the countries listed below.

Ingredient matches for Metoprolol Heumann

Metoprolol

Metoprolol tartrate (a derivative of Metoprolol) is reported as an ingredient of Metoprolol Heumann in the following countries:

• Germany

International Drug Name Search

Capozide 50 / 15

See also: Generic Capozide 25/15, Generic Capozide 25/25, Generic Capozide 50/25

Capozide 50/15 is a brand name of captopril/hydrochlorothiazide, approved by the FDA in the following formulation(s):

CAPOZIDE 50/15 (captopril; hydrochlorothiazide - tablet; oral)

• 
  Manufacturer: APOTHECON
  
  Approval date: October 12, 1984
  
  Strength(s): 50MG;15MG ^[RLD][AB]

Has a generic version of Capozide 50/15 been approved?

Yes. The following products are equivalent to Capozide 50/15:

CAPTOPRIL AND HYDROCHLOROTHIAZIDE (captopril; hydrochlorothiazide tablet; oral)

• 
  Manufacturer: MYLAN
  
  Approval date: December 29, 1997
  
  Strength(s): 50MG;15MG ^[AB]


• 
  Manufacturer: TEVA
  
  Approval date: December 29, 1997
  
  Strength(s): 50MG;15MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Capozide 50/15. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Capozide 50/15.

See also...

• Capozide 50/15 Consumer Information (Cerner Multum)
• Capozide 50/15 Advanced Consumer Information (Micromedex)
• Captopril/Hydrochlorothiazide Consumer Information (Wolters Kluwer)
• Hydrochlorothiazide and captopril Consumer Information (Cerner Multum)
• Captopril and hydrochlorothiazide Advanced Consumer Information (Micromedex)

Hyoscine Butylbromide

Hyoscine Butylbromide may be available in the countries listed below.

Ingredient matches for Hyoscine Butylbromide

Scopolamine

Hyoscine Butylbromide (BANM) is known as Scopolamine in the US.

International Drug Name Search

Glossary

BANM	British Approved Name (Modified)

Click for further information on drug naming conventions and International Nonproprietary Names.

Erytromicina

Erytromicina may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Erytromicina

Erythromycin

Erythromycin is reported as an ingredient of Erytromicina in the following countries:

• Italy

International Drug Name Search

Yaz

In the US, Yaz (drospirenone/ethinyl estradiol systemic) is a member of the drug class contraceptives and is used to treat Acne, Birth Control, Menstrual Disorders, Polycystic Ovary Syndrome and Premenstrual Dysphoric Disorder.

US matches:

• Yaz


• Yaz 28

Ingredient matches for Yaz

Drospirenone

Drospirenone is reported as an ingredient of Yaz in the following countries:

• Australia


• Austria


• Belgium


• Germany


• Indonesia


• Ireland


• Netherlands


• New Zealand


• Poland


• Slovakia


• Sweden


• Switzerland


• United States

Ethinylestradiol

Ethinylestradiol is reported as an ingredient of Yaz in the following countries:

• Belgium


• Indonesia


• Netherlands


• New Zealand


• Poland

Ethinylestradiol betadex (a derivative of Ethinylestradiol) is reported as an ingredient of Yaz in the following countries:

• Australia


• Austria


• Germany


• Ireland


• Slovakia


• Sweden


• Switzerland


• United States

International Drug Name Search

Zeto

Zeto may be available in the countries listed below.

Ingredient matches for Zeto

Azithromycin

Azithromycin is reported as an ingredient of Zeto in the following countries:

• Israel

International Drug Name Search

Lebel

Lebel may be available in the countries listed below.

Ingredient matches for Lebel

Levofloxacin

Levofloxacin is reported as an ingredient of Lebel in the following countries:

• Turkey

International Drug Name Search

Oxaliplatino Teva

Oxaliplatino Teva may be available in the countries listed below.

Ingredient matches for Oxaliplatino Teva

Oxaliplatin

Oxaliplatin is reported as an ingredient of Oxaliplatino Teva in the following countries:

• Italy


• Spain

International Drug Name Search

Gentamicina Sulfato

Gentamicina Sulfato may be available in the countries listed below.

Ingredient matches for Gentamicina Sulfato

Gentamicin

Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Gentamicina Sulfato in the following countries:

• Chile

International Drug Name Search

Blubatosine

Blubatosine may be available in the countries listed below.

Ingredient matches for Blubatosine

Arbekacin

Arbekacin sulfate (a derivative of Arbekacin) is reported as an ingredient of Blubatosine in the following countries:

• Japan

International Drug Name Search

Zaditen

Zaditen may be available in the countries listed below.

UK matches:

• ZADITEN Elixir (SPC)
• Zaditen Elixir 1mg/5ml (SPC)
• Zaditen Eye Drops (SPC)
• ZADITEN Tablets (SPC)
• Zaditen Tablets 1mg (SPC)

Ingredient matches for Zaditen

Ketoprofen

Ketoprofen is reported as an ingredient of Zaditen in the following countries:

• Tunisia

Ketotifen

Ketotifen is reported as an ingredient of Zaditen in the following countries:

• Luxembourg


• South Africa


• Taiwan


• Yemen

Ketotifen fumarate (a derivative of Ketotifen) is reported as an ingredient of Zaditen in the following countries:

• Argentina


• Australia


• Austria


• Bahrain


• Belgium


• Brazil


• Canada


• Chile


• Colombia


• Croatia (Hrvatska)


• Czech Republic


• Denmark


• Ecuador


• Egypt


• Finland


• France


• Germany


• Ghana


• Greece


• Guyana


• Hong Kong


• Hungary


• Iceland


• Indonesia


• Iran


• Iraq


• Ireland


• Israel


• Italy


• Japan


• Jordan


• Kenya


• Kuwait


• Latvia


• Lebanon


• Libya


• Lithuania


• Luxembourg


• Malaysia


• Malta


• Mexico


• Netherlands


• New Zealand


• Nigeria


• Norway


• Oman


• Philippines


• Poland


• Portugal


• Qatar


• Romania


• Russian Federation


• Saudi Arabia


• Singapore


• Slovakia


• Slovenia


• South Africa


• Spain


• Sudan


• Sweden


• Switzerland


• Syria


• Tanzania


• Thailand


• Turkey


• United Arab Emirates


• United Kingdom


• Venezuela


• Zimbabwe

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Pepzer-O

Pepzer-O may be available in the countries listed below.

Ingredient matches for Pepzer-O

Omeprazole

Omeprazole is reported as an ingredient of Pepzer-O in the following countries:

• India

International Drug Name Search

Perfenazina

Perfenazina may be available in the countries listed below.

Ingredient matches for Perfenazina

Perphenazine

Perfenazina (DCIT) is known as Perphenazine in the US.

International Drug Name Search

Glossary

DCIT	Denominazione Comune Italiana

Click for further information on drug naming conventions and International Nonproprietary Names.

Bicillin L-A

Bicillin L-A is a brand name of penicillin, approved by the FDA in the following formulation(s):

BICILLIN L-A (penicillin g benzathine - injectable; injection)

• 
  Manufacturer: KING PHARMS
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 300,000 UNITS/ML ^[RLD]

Has a generic version of Bicillin L-A been approved?

No. There is currently no therapeutically equivalent version of Bicillin L-A available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bicillin L-A. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Bicillin L-A.

See also...

• Bicillin L-A Suspension Consumer Information (Wolters Kluwer)
• Bicillin L-A Consumer Information (Cerner Multum)
• Bicillin L-A Advanced Consumer Information (Micromedex)
• Penicillin Consumer Information (Drugs.com)
• Bicillin C-R Suspension Consumer Information (Wolters Kluwer)
• Penicillin G Benzathine Suspension Consumer Information (Wolters Kluwer)
• Penicillin G Benzathine/Penicillin G Procaine Suspension Consumer Information (Wolters Kluwer)
• Penicillin G Potassium Consumer Information (Wolters Kluwer)
• Penicillin G Sodium Consumer Information (Wolters Kluwer)
• Penicillin V Potassium Consumer Information (Wolters Kluwer)
• Penicillin V Potassium Solution Consumer Information (Wolters Kluwer)
• Penicillin-VK Consumer Information (Wolters Kluwer)
• Penicillin-VK Solution Consumer Information (Wolters Kluwer)
• Penicillin G benzathine Consumer Information (Cerner Multum)
• Penicillin G potassium Consumer Information (Cerner Multum)
• Penicillin G potassium injection Consumer Information (Cerner Multum)
• Penicillin G sodium Consumer Information (Cerner Multum)
• Penicillin V Consumer Information (Cerner Multum)
• Penicillin V potassium Consumer Information (Cerner Multum)
• Amoxil Advanced Consumer Information (Micromedex)
• Amoxil Pediatric Advanced Consumer Information (Micromedex)
• Ampicillin Sodium Advanced Consumer Information (Micromedex)
• Apo-Amoxi Advanced Consumer Information (Micromedex)
• Apo-Amoxi Sugar-Free Advanced Consumer Information (Micromedex)
• Apo-Cloxi Advanced Consumer Information (Micromedex)
• Apo-Pen-Vk Advanced Consumer Information (Micromedex)
• Bactocill Advanced Consumer Information (Micromedex)
• Cloxapen Advanced Consumer Information (Micromedex)
• Crysticillin Advanced Consumer Information (Micromedex)
• Dynapen Advanced Consumer Information (Micromedex)
• Gen-Amoxicillin Advanced Consumer Information (Micromedex)
• Geocillin Advanced Consumer Information (Micromedex)
• Med Amoxicillin Advanced Consumer Information (Micromedex)
• Nadopen V 200 Advanced Consumer Information (Micromedex)
• Nadopen V 400 Advanced Consumer Information (Micromedex)
• Nafcil Advanced Consumer Information (Micromedex)
• Novamoxin Advanced Consumer Information (Micromedex)
• Pipracil Advanced Consumer Information (Micromedex)
• Principen Advanced Consumer Information (Micromedex)
• Staphcillin Advanced Consumer Information (Micromedex)
• Ticar Advanced Consumer Information (Micromedex)
• Penicillin Oral, Injection, Intravenous, Intramuscular Advanced Consumer Information (Micromedex)
• Penicillin G Benzathine/Potassium/Sodium AHFS DI Monographs (ASHP)
• Penicillin V AHFS DI Monographs (ASHP)
• Penicillin V Potassium AHFS DI Monographs (ASHP)

Acuilfem

Acuilfem may be available in the countries listed below.

Ingredient matches for Acuilfem

Ibuprofen

Ibuprofen is reported as an ingredient of Acuilfem in the following countries:

• Argentina

International Drug Name Search

Solarsal

Solarsal may be available in the countries listed below.

Ingredient matches for Solarsal

Oxymetazoline

Oxymetazoline hydrochloride (a derivative of Oxymetazoline) is reported as an ingredient of Solarsal in the following countries:

• Venezuela

International Drug Name Search

Lutrelef

Lutrelef may be available in the countries listed below.

Ingredient matches for Lutrelef

Gonadorelin

Gonadorelin acetate (a derivative of Gonadorelin) is reported as an ingredient of Lutrelef in the following countries:

• Austria


• France


• Germany


• Israel


• Italy


• Netherlands


• Sweden


• Switzerland

International Drug Name Search

Volon

Volon may be available in the countries listed below.

Ingredient matches for Volon

Triamcinolone

Triamcinolone is reported as an ingredient of Volon in the following countries:

• Austria


• Germany

International Drug Name Search

Gastrosorb

Gastrosorb may be available in the countries listed below.

Ingredient matches for Gastrosorb

Attapulgite

Attapulgite activated (a derivative of Attapulgite) is reported as an ingredient of Gastrosorb in the following countries:

• Hong Kong

International Drug Name Search

Micardis

In the US, Micardis (telmisartan systemic) is a member of the drug class angiotensin II inhibitors and is used to treat Cardiovascular Risk Reduction, High Blood Pressure and Prevention of Cardiovascular Disease.

US matches:

• Micardis


• Micardis HCT

UK matches:

• Micardis 20mg Tablets
• Micardis 40mg Tablets
• Micardis 80mg Tablets
• Micardis 20mg, 40mg and 80mg tablets (SPC)

Ingredient matches for Micardis

Telmisartan

Telmisartan is reported as an ingredient of Micardis in the following countries:

• Argentina


• Australia


• Austria


• Bahrain


• Belgium


• Brazil


• Canada


• Chile


• China


• Colombia


• Costa Rica


• Croatia (Hrvatska)


• Cyprus


• Czech Republic


• Denmark


• Dominican Republic


• Egypt


• El Salvador


• Finland


• France


• Germany


• Greece


• Guatemala


• Honduras


• Hong Kong


• Hungary


• Indonesia


• Iraq


• Ireland


• Italy


• Japan


• Jordan


• Kenya


• Kuwait


• Lebanon


• Libya


• Luxembourg


• Malaysia


• Mexico


• Netherlands


• Nicaragua


• Norway


• Oman


• Panama


• Peru


• Poland


• Portugal


• Qatar


• Romania


• Russian Federation


• Saudi Arabia


• Serbia


• Singapore


• Slovakia


• Slovenia


• South Africa


• Spain


• Sudan


• Sweden


• Switzerland


• Taiwan


• Thailand


• Turkey


• United Arab Emirates


• United Kingdom


• United States


• Venezuela


• Vietnam


• Yemen

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Gen-Indapamide

Gen-Indapamide may be available in the countries listed below.

Ingredient matches for Gen-Indapamide

Indapamide

Indapamide hemihydrate (a derivative of Indapamide) is reported as an ingredient of Gen-Indapamide in the following countries:

• Canada

International Drug Name Search

Ondansetron 1A Farma

Ondansetron 1A Farma may be available in the countries listed below.

Ingredient matches for Ondansetron 1A Farma

Ondansetron

Ondansetron hydrochloride dihydrate (a derivative of Ondansetron) is reported as an ingredient of Ondansetron 1A Farma in the following countries:

• Denmark

International Drug Name Search

Spiramycine Métronidazole Ranbaxy

Spiramycine Métronidazole Ranbaxy may be available in the countries listed below.

Ingredient matches for Spiramycine Métronidazole Ranbaxy

Metronidazole

Metronidazole is reported as an ingredient of Spiramycine Métronidazole Ranbaxy in the following countries:

• France

Spiramycin

Spiramycin is reported as an ingredient of Spiramycine Métronidazole Ranbaxy in the following countries:

• France

International Drug Name Search

Fexin

Fexin may be available in the countries listed below.

Ingredient matches for Fexin

Ferrous Gluconate

Ferrous Gluconate is reported as an ingredient of Fexin in the following countries:

• Denmark


• Finland


• Norway

International Drug Name Search

Novabupi

Novabupi may be available in the countries listed below.

Ingredient matches for Novabupi

Levobupivacaine

Levobupivacaine is reported as an ingredient of Novabupi in the following countries:

• Brazil

International Drug Name Search

Biopeg

Biopeg may be available in the countries listed below.

Ingredient matches for Biopeg

Macrogol

Macrogol is reported as an ingredient of Biopeg in the following countries:

• France

International Drug Name Search

Clopidogrel Arrow

Clopidogrel Arrow may be available in the countries listed below.

Ingredient matches for Clopidogrel Arrow

Clopidogrel

Clopidogrel besilate (a derivative of Clopidogrel) is reported as an ingredient of Clopidogrel Arrow in the following countries:

• Germany

International Drug Name Search

Cefpiramide

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

J01DD11

CAS registry number (Chemical Abstracts Service)

0070797-11-4

Chemical Formula

C25-H24-N8-O7-S2

Molecular Weight

612

Therapeutic Category

Antibacterial: Cephalosporin

Chemical Name

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[[(4-hydroxy-6-methyl-3-pyridinyl)-carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6α,-7ß(R*)]]-

Foreign Names

• Cefpiramidum (Latin)
• Cefpiramid (German)
• Cefpiramide (French)
• Cefpiramida (Spanish)

Generic Names

• Cefpiramide (OS: DCF, USAN)
• CPM (IS)
• Wy 44635 (IS: Wyeth)
• Cefpiramide (PH: USP 32)
• Cefpiramide Sodium (OS: USAN, JAN)
• SM 1652 (IS: Sumitomo)
• Cefpiramide Sodium (PH: JP XV)

Brand Names

• Sepatren
  Dainippon Sumitomo, Japan



• Tamicin
  Lek, Slovenia

International Drug Name Search

Glossary

DCF	Dénomination Commune Française
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Butacaine

In some countries, this medicine may only be approved for veterinary use.

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0000149-16-6

Chemical Formula

C18-H30-N2-O2

Molecular Weight

306

Therapeutic Category

Anesthetic, local

Chemical Name

1-Propanol, 3-(dibutylamino)-, 4-aminobenzoate (ester)

Foreign Names

• Butacainum (Latin)
• Butacain (German)
• Butacaïne (French)
• Butacaina (Spanish)

Generic Names

• Butacaina (OS: DCIT)
• Butacaine (OS: BAN)
• Butacaïne (OS: DCF)
• Butacaine Sulfate (OS: USAN)
• Butacaine Sulphate (IS)
• Butacaine Sulfate (PH: USP XX)

Brand Names

• Bal (Butacaine and Dimercaprol)
  SERB, France



• Nitrofurazone (Butacaine and Nitrofural (veterinary use))
  Med Pharmex, United States

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Rilexine

Rilexine may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Rilexine

Cefalexin

Cefalexin is reported as an ingredient of Rilexine in the following countries:

• Austria


• Belgium


• Luxembourg


• Netherlands


• New Zealand


• Portugal


• South Africa


• United Kingdom

Cefalexin benzathine (a derivative of Cefalexin) is reported as an ingredient of Rilexine in the following countries:

• Austria


• Belgium


• France


• Italy

Cefalexin lysine salt (a derivative of Cefalexin) is reported as an ingredient of Rilexine in the following countries:

• France

Cefalexin monohydrate (a derivative of Cefalexin) is reported as an ingredient of Rilexine in the following countries:

• Australia


• Austria


• Belgium


• Finland


• France


• Germany


• Italy


• Netherlands


• New Zealand


• South Africa


• Switzerland

Neomycin

Neomycin sulfate (a derivative of Neomycin) is reported as an ingredient of Rilexine in the following countries:

• South Africa

Prednisolone

Prednisolone is reported as an ingredient of Rilexine in the following countries:

• South Africa

International Drug Name Search

Cetrimonio bromuro

Cetrimonio bromuro may be available in the countries listed below.

Ingredient matches for Cetrimonio bromuro

Cetrimonium

Cetrimonio bromuro (DCIT) is also known as Cetrimonium (DCF)

International Drug Name Search

Glossary

DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana

Click for further information on drug naming conventions and International Nonproprietary Names.

Calcium Vitamine D3 ratiopharm

Calcium Vitamine D3 ratiopharm may be available in the countries listed below.

Ingredient matches for Calcium Vitamine D3 ratiopharm

Calcium Carbonate

Calcium Carbonate is reported as an ingredient of Calcium Vitamine D3 ratiopharm in the following countries:

• France

Colecalciferol

Colecalciferol is reported as an ingredient of Calcium Vitamine D3 ratiopharm in the following countries:

• France

International Drug Name Search

Dexamethasone Tablets (Dose Pack)

Pronunciation: dex-a-METH-a-sone
Generic Name: Dexamethasone
Brand Name: Examples include Decadron Dose Pack and DexPak

Dexamethasone is used for:

Treating certain conditions associated with decreased adrenal gland function. It is also used to treat severe inflammation due to certain conditions, including severe asthma, severe allergies, rheumatoid arthritis, ulcerative colitis, certain blood disorders, lupus, multiple sclerosis, and certain eye and skin conditions. It may also be used for other conditions as determined by your doctor.

Dexamethasone is a corticosteroid. It works by decreasing or preventing tissues from responding to inflammation. It also modifies the body's response to certain immune stimulation.

Do NOT use Dexamethasone if:

• you are allergic to any ingredient in Dexamethasone


• you have a systemic fungal infection


• you are taking mifepristone

Contact your doctor or health care provider right away if any of these apply to you.

Before using Dexamethasone:

Some medical conditions may interact with Dexamethasone. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you are scheduled for a vaccination with a live virus vaccine (eg, smallpox)


• if you have an underactive thyroid, liver or kidney problems, diabetes, or ulcerative colitis


• if you have heart problems, esophagitis, gastritis, stomach obstruction or perforation, or an ulcer


• if you have a history of mental problems (eg, depression), glaucoma, cataracts, or other eye problems


• if you have a herpes infection in your eye or any other type of infection (bacterial, fungal, or viral); have or recently had tuberculosis (TB) or tested positive for TB, measles, or chickenpox

Some MEDICINES MAY INTERACT with Dexamethasone. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Barbiturates (eg, phenobarbital), carbamazepine, hydantoins (eg, phenytoin), or rifampin because they may decrease Dexamethasone's effectiveness


• Clarithromycin, azole antifungals (eg, ketoconazole), steroidal contraceptives (eg, desogestrel), or troleandomycin because because weakness, confusion, muscle aches, joint pain, or low blood sugar, may occur


• Methotrexate or ritodrine because the risk of their side effects may be increased by Dexamethasone


• Hydantoins (eg, phenytoin),mifepristone, or live vaccines because their effectiveness may be decreased by Dexamethasone


• Anticoagulants (eg, warfarin) or aspirin because their actions and side effects may be increased or decreased by Dexamethasone

This may not be a complete list of all interactions that may occur. Ask your health care provider if Dexamethasone may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Dexamethasone:

Use Dexamethasone as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Dexamethasone by mouth with food.


• Dexamethasone is a dose pack. Unless otherwise directed by your doctor, follow the instructions on the pack for taking Dexamethasone.


• If you miss a dose of Dexamethasone, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Dexamethasone.

Important safety information:

• Dexamethasone may lower the ability of your body to fight infection. Avoid contact with people who have colds or infections. Tell your doctor if you notice signs of infection like fever, sore throat, rash, or chills.


• Tell your doctor or dentist that you take Dexamethasone before you receive any medical or dental care, emergency care, or surgery.


• Dexamethasone may cause an elevation in blood pressure, salt and water retention, and increased potassium loss. You may need to restrict the use of salt and take a calcium supplement.


• Dexamethasone can cause calcium loss and promote the development of osteoporosis. Take adequate calcium and vitamin D supplements.


• Diabetes patients -- Dexamethasone may affect your blood sugar. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine.


• Caution is advised when using Dexamethasone in CHILDREN; they may be more sensitive to its effects.


• Corticosteroids may affect growth rate in CHILDREN and teenagers in some cases. They may need regular growth checks while they take Dexamethasone.


• PREGNANCY and BREAST-FEEDING: It is not known if Dexamethasone can cause harm to the fetus. If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Dexamethasone while you are pregnant. Dexamethasone is found in breast milk. Do not breast-feed while taking Dexamethasone.

Possible side effects of Dexamethasone:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Difficulty sleeping; feeling of a whirling motion; increased appetite; increased sweating; indigestion; mood changes; nervousness.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); appetite loss; black, tarry stools; changes in menstrual periods; convulsions; depression; diarrhea; dizziness; exaggerated sense of well-being; fever; general body discomfort; headache; increased pressure in the eye; joint or muscle pain; mood swings; muscle weakness; personality changes; prolonged sore throat, cold, or fever; puffing of the face; severe nausea or vomiting; swelling of feet or legs; unusual weight gain; vomiting material that looks like coffee grounds; weakness; weight loss.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.

Proper storage of Dexamethasone:

Store Dexamethasone at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Dexamethasone out of the reach of children and away from pets.

General information:

• If you have any questions about Dexamethasone, please talk with your doctor, pharmacist, or other health care provider.


• Dexamethasone is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Dexamethasone. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Dexamethasone resources

• Dexamethasone Use in Pregnancy & Breastfeeding
• Drug Images
• Dexamethasone Drug Interactions
• Dexamethasone Support Group
• 12 Reviews for Dexamethasone - Add your own review/rating

Compare Dexamethasone with other medications

• Addison's Disease
• Adrenal Insufficiency
• Adrenocortical Insufficiency
• Adrenogenital Syndrome
• Ankylosing Spondylitis
• Aphthous Ulcer
• Aspiration Pneumonia
• Asthma
• Asthma, acute
• Atopic Dermatitis
• Bronchopulmonary Dysplasia
• Bursitis
• Cerebral Edema
• Chorioretinitis
• Croup
• Cushing's Syndrome
• Dermatitis Herpetiformis
• Eczema
• Epicondylitis, Tennis Elbow
• Erythroblastopenia
• Evan's Syndrome
• Gouty Arthritis
• Hay Fever
• Hemolytic Anemia
• Hypercalcemia of Malignancy
• Idiopathic Thrombocytopenic Purpura
• Inflammatory Bowel Disease
• Inflammatory Conditions
• Iridocyclitis
• Iritis
• Juvenile Rheumatoid Arthritis
• Keratitis
• Leukemia
• Loeffler's Syndrome
• Lymphoma
• Meningitis, Haemophilus influenzae
• Meningitis, Listeriosis
• Meningitis, Meningococcal
• Meningitis, Pneumococcal
• Mountain Sickness / Altitude Sickness
• Multiple Myeloma
• Multiple Sclerosis
• Mycosis Fungoides
• Nausea/Vomiting, Chemotherapy Induced
• Neurosarcoidosis
• Pemphigus
• Psoriatic Arthritis
• Pulmonary Tuberculosis
• Rheumatoid Arthritis
• Sarcoidosis
• Seborrheic Dermatitis
• Shock
• Synovitis
• Systemic Lupus Erythematosus
• Thrombocytopenia
• Toxic Epidermal Necrolysis
• Tuberculous Meningitis
• Ulcerative Colitis
• Uveitis, Posterior

Oxycodone Extended-Release Tablets

Generic Name: oxycodone hydrochloride

Dosage Form: tablet, film coated, extended release
OXYCODONE HCl CONTROLLED-RELEASE TABLETS CII

10 mg, 20 mg, 40 mg and * 80 mg

*80 mg, and 160 mg is for use in opioid-tolerant patients only

WARNING:

Oxycodone HCl Controlled-Release Tablets are an opioid agonist and a Schedule II controlled substance with an abuse liability similar to morphine.

Oxycodone can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing Oxycodone HCl Controlled-Release Tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

Oxycodone HCl Controlled-Release Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time.

Oxycodone HCl Controlled-Release Tabletsare NOT intended for use as a prn analgesic.

OXYCODONE HCl CONTROLLED-RELEASE 80 mg, and 160 mg Tablets, or a single dose greater than 40 mg, ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY. A single dose greater than 40 mg, or total daily doses greater than 80 mg, may cause fatal respiratory depression when administered to patients who are not tolerant to the respiratory depressant effects of opioids.

OXYCODONE HCl CONTROLLED-RELEASE TABLETS ARE TO BE SWALLOWED WHOLE AND ARE NOT TO BE BROKEN, CHEWED, OR CRUSHED. TAKING BROKEN, CHEWED, OR CRUSHED OXYCODONE HCl CONTROLLED-RELEASE TABLETS LEADS TO RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF OXYCODONE.

Oxycodone Extended-Release Tablets Description

Oxycodone HCl Controlled-Release Tablets are an opioid analgesic supplied in 10 mg, 20 mg, 40 mg, and 80 mg tablet strengths for oral administration.  The tablet strengths describe the amount of oxycodone per tablet as the hydrochloride salt.  The structural formula for oxycodone hydrochloride is as follows:

The chemical formula is 4, 5α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride.

Oxycodone is a white, odorless crystalline powder derived from the opium alkaloid, thebaine.  Oxycodone hydrochloride dissolves in water (1 g in 6 to 7 mL).  It is slightly soluble in alcohol (octanol water partition coefficient 0.7).  The tablets contain the following inactive ingredients: ammonio methacrylate copolymer, hypromellose, lactose, magnesium stearate, polyethylene glycol 400, povidone, sodium hydroxide, sorbic acid, stearyl alcohol, talc, titanium dioxide, and triacetin.

The 10 mg tablets also contain: hydroxypropyl cellulose. 

The 20 mg tablets also contain: polysorbate 80 and red iron oxide. 

The 40 mg tablets also contain: polysorbate 80 and yellow iron oxide. 

The 80 mg tablets also contain:  FD&C blue No. 2, hydroxypropyl cellulose, and yellow iron oxide.

Oxycodone HCl controlled-release 10 mg, 20 mg, 40 mg, and 80 mg tablets are tested using USP Dissolution Test 2 and meet the associated tolerances provided in Acceptance Table 2 of the Oxycodone Hydrochloride Extended-Release Tablets USP Monograph.

Oxycodone Extended-Release Tablets - Clinical Pharmacology

Oxycodone is a pure agonist opioid whose principal therapeutic action is analgesia.  Other members of the class known as opioid agonists include substances such as morphine, hydromorphone, fentanyl, codeine, and hydrocodone.  Pharmacological effects of opioid agonists include anxiolysis, euphoria, feelings of relaxation, respiratory depression, constipation, miosis, and cough suppression, as well as analgesia.  Like all pure opioid agonist analgesics, with increasing doses there is increasing analgesia, unlike with mixed agonist/antagonists or non-opioid analgesics, where there is a limit to the analgesic effect with increasing doses.  With pure opioid agonist analgesics, there is no defined maximum dose; the ceiling to analgesic effectiveness is imposed only by side effects, the more serious of which may include somnolence and respiratory depression.

Central Nervous System

The precise mechanism of the analgesic action is unknown.  However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and play a role in the analgesic effects of this drug. 

Oxycodone produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves both a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation. 

Oxycodone depresses the cough reflex by direct effect on the cough center in the medulla.  Antitussive effects may occur with doses lower than those usually required for analgesia. 

Oxycodone causes miosis, even in total darkness.  Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings).  Marked mydriasis rather than miosis may be seen with hypoxia in the setting of Oxycodone HCl Controlled-Release Tablets overdose (See OVERDOSAGE).

Gastrointestinal Tract And Other Smooth Muscle

Oxycodone causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum.  Digestion of food in the small intestine is delayed and propulsive contractions are decreased.  Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation.  Other opioid-induced effects may include a reduction in gastric, biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase.

Cardiovascular System

Oxycodone may produce release of histamine with or without associated peripheral vasodilation.  Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.

Concentration – Efficacy Relationships

Studies in normal volunteers and patients reveal predictable relationships between oxycodone dosage and plasma oxycodone concentrations, as well as between concentration and certain expected opioid effects, such as pupillary constriction, sedation, overall “drug effect”, analgesia and feelings of “relaxation”.

As with all opioids, the minimum effective plasma concentration for analgesia will vary widely among patients, especially among patients who have been previously treated with potent agonist opioids.  As a result, patients must be treated with individualized titration of dosage to the desired effect.  The minimum effective analgesic concentration of oxycodone for any individual patient may increase over time due to an increase in pain, the development of a new pain syndrome and/or the development of analgesic tolerance.

Concentration – Adverse Experience Relationships

Oxycodone HCl Controlled-Release Tablets are associated with typical opioid-related adverse experiences. There is a general relationship between increasing oxycodone plasma concentration and increasing frequency of dose-related opioid adverse experiences such as nausea, vomiting, CNS effects, and respiratory depression. In opioid-tolerant patients, the situation is altered by the development of tolerance to opioid-related side effects, and the relationship is not clinically relevant. 

As with all opioids, the dose must be individualized (see DOSAGE AND ADMINISTRATION), because the effective analgesic dose for some patients will be too high to be tolerated by other patients.

PHARMACOKINETICS AND METABOLISM

The activity of Oxycodone HCl Controlled-Release Tablets is primarily due to the parent drug oxycodone.  Oxycodone HCl Controlled-Release Tablets are designed to provide controlled delivery of oxycodone over 12 hours.   

Breaking, chewing or crushing Oxycodone HCl Controlled-Release Tablets eliminates the controlled delivery mechanism and results in the rapid release and absorption of a potentially fatal dose of oxycodone. 

Oxycodone release from Oxycodone HCl Controlled-Release Tablets is pH independent.  Oxycodone is well absorbed from Oxycodone HCl Controlled-Release Tablets with an oral bioavailability of 60% to 87%.  The relative oral bioavailability of Oxycodone HCl Controlled-Release Tablets to immediate-release oral dosage forms is 100%.  Upon repeated dosing in normal volunteers in pharmacokinetic studies, steady-state levels were achieved within 24-36 hours.  Dose proportionality and/or bioavailability has been established for the 10 mg, 20 mg, 40 mg, 80 mg, and 160 mg tablet strengths for both peak plasma levels (Cmax) and extent of absorption (AUC).  Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated metabolites.  The apparent elimination half-life of oxycodone following the administration of Oxycodone HCl Controlled-Release Tablets was 4.5 hours compared to 3.2 hours for immediate-release oxycodone..

Absorption

About 60% to 87% of an oral dose of oxycodone reaches the central compartment in comparison to a parenteral dose.  This high oral bioavailability is due to low pre-systemic and/or first-pass metabolism.  In normal volunteers, the t½ of absorption is 0.4 hours for immediate-release oral oxycodone.  In contrast, Oxycodone HCl Controlled-Release Tablets exhibit a biphasic absorption pattern with two apparent absorption half-lives of 0.6 and 6.9 hours, which describes the initial release of oxycodone from the tablet followed by a prolonged release.

Plasma Oxycodone by Time

Dose proportionality has been established for the 10 mg, 20 mg, 40 mg, and 80 mg tablet strengths for both peak plasma concentrations (Cmax) and extent of absorption (AUC) (see Table 1 below). Another study established that the 160 mg tablet is bioequivalent to 2 x 80 mg tablets as well as to 4 x 40 mg for both peak plasma concentrations (Cmax) and extent of absorption (AUC) (see Table 2 below). Given the short half-life of elimination of oxycodone from Oxycodone HCl Controlled-Release Tablets, steady-state plasma concentrations of oxycodone are achieved within 24-36 hours of initiation of dosing with Oxycodone HCl Controlled-Release Tablets.  In a study comparing 10 mg of Oxycodone HCl Controlled-Release Tablets every 12 hours to 5 mg of immediate-release oxycodone every 6 hours, the two treatments were found to be equivalent for AUC and Cmax, and similar for Cmin (trough) concentrations. 

TABLE 1 Mean [% coefficient variation]

Regimen/	Dosage Form	AUC (ng•hr/mL)†	Cmax (ng/mL)	Tmax (hrs)	Trough Conc. (ng/mL)
Single Dose	10 mg Oxycodone HCl Controlled-Release Tablets	100.7 [26.6]	10.6 [20.1]	2.7 [44.1]	n.a.
	20 mg Oxycodone HCl Controlled-Release Tablets	207.5 [35.9]	21.4 [36.6]	3.2 [57.9]	n.a.
	40 mg Oxycodone HCl Controlled-Release Tablets	423.1 [33.3]	39.3 [34.0]	3.1 [77.4]	n.a.
	80 mg Oxycodone HCl Controlled-Release Tablets*	1085.5 [32.3]	98.5 [32.1]	2.1 [52.3]	n.a.
Multiple Dose	10 mg Oxycodone HCl Controlled-Release Tablets q12h	103.6 [38.6]	15.1 [31.0]	3.2 [69.5]	7.2 [48.1]
	5 mg immediate-    release q6h	99.0 [36.2]	15.5 [28.8]	1.6 [49.7]	7.4 [50.9]

TABLE 2 Mean [% coefficient variation]

Regimen/	Dosage Form	AUC∞ (ng•hr/mL)†	Cmax (ng/mL)	Tmax (hrs)	Trough Conc. (ng/mL)
† for single-dose AUC = AUC0-inf; for multiple-dose AUC = AUC0-T
* data obtained while volunteers received naltrexone which can enhance absorption
Single Dose	4 x 40 mg Oxycodone HCl Controlled-Release Tablets*	1935.3 [34.7]	152.0 [28.9]	2.56 [42.3]	n.a.
	2 x 80 mg Oxycodone HCl Controlled-Release Tablets*	1859.3 [30.1]	153.4 [25.1]	2.78 [69.3]	n.a.
	1 x 160 mg Oxycodone HCl Controlled-Release Tablets*	1856.4 [30.5]	156.4 [24.8]	2.54 [36.4]	n.a.

Oxycodone HCl Controlled-Release Tablets are NOT INDICATED FOR RECTAL ADMINISTRATION.  Data from a study involving 21 normal volunteers show that Oxycodone HCl Controlled-Release Tablets administered per rectum resulted in an AUC 39% greater and a Cmax 9% higher than tablets administered by mouth.  Therefore, there is an increased risk of adverse events with rectal administration.

Food Effects

Food has no significant effect on the extent of absorption of oxycodone from Oxycodone HCl Controlled-Release Tablets.  However, the peak plasma concentration of oxycodone increased by 25% when an Oxycodone HCl Controlled-Release Tablets 160 mg Tablet was administered with a high-fat meal.

Distribution

Following intravenous administration, the volume of distribution (Vss) for oxycodone was 2.6 L/kg.  Oxycodone binding to plasma protein at 37°C and a pH of 7.4 was about 45%.  Once absorbed, oxycodone is distributed to skeletal muscle, liver, intestinal tract, lungs, spleen, and brain.  Oxycodone has been found in breast milk (see PRECAUTIONS).

Metabolism

Oxycodone hydrochloride is extensively metabolized to noroxycodone, oxymorphone, noroxymorphone, and their glucuronides.  The major circulating metabolite is noroxycodone.  Noroxycodone is reported to be a considerably weaker analgesic than oxycodone.  Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations.  The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations.  The analgesic activity profile of other metabolites is not known.  

CYP3A mediated N-demethylation (to noroxycodone) is the primary metabolic pathway of oxycodone with a lower contribution from CYP2D6 mediated O-demethylation (to oxymorphone).  Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs (see Drug-Drug Interactions).

Excretion

Oxycodone and its metabolites are excreted primarily via the kidney.  The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone ≤ 14%; both free and conjugated noroxycodone have been found in the urine but not quantified.  The total plasma clearance was 0.8 L/min for adults.

Special Populations

Elderly

The plasma concentrations of oxycodone are only nominally affected by age, being 15% greater in elderly as compared to young subjects.

Gender

Female subjects have, on average, plasma oxycodone concentrations up to 25% higher than males on a body weight adjusted basis. The reason for this difference is unknown.

Renal Impairment

Data from a pharmacokinetic study involving 13 patients with mild to severe renal dysfunction (creatinine clearance <60 mL/min) show peak plasma oxycodone and noroxycodone concentrations 50% and 20% higher, respectively, and AUC values for oxycodone, noroxycodone, and oxymorphone 60%, 50%, and 40% higher than normal subjects, respectively. This is accompanied by an increase in sedation but not by differences in respiratory rate, pupillary constriction, or several other measures of drug effect. There was an increase in t½ of elimination for oxycodone of only 1 hour (see PRECAUTIONS).

Hepatic Impairment

Data from a study involving 24 patients with mild to moderate hepatic dysfunction show peak plasma oxycodone and noroxycodone concentrations 50% and 20% higher, respectively, than normal subjects. AUC values are 95% and 65% higher, respectively. Oxymorphone peak plasma concentrations and AUC values are lower by 30% and 40%. These differences are accompanied by increases in some, but not other, drug effects. The t½ elimination for oxycodone increased by 2.3 hours (see PRECAUTIONS).

Drug-Drug Interactions (see PRECAUTIONS)

CYP3A mediated N-demethylation is the principal metabolic pathway of oxycodone with a lower contribution from CYP2D6 mediated O-demethylation and in theory can be affected by drugs affecting cytochrome P450 enzymes. 

Oxycodone is metabolized in part by cytochrome P450 2D6 to oxymorphone which represents less than 15% of the total administered dose.  This route of elimination may be blocked by a variety of drugs (e.g., certain cardiovascular drugs including amiodarone and quinidine as well as polycyclic anti-depressants).  However, in a study involving 10 subjects using quinidine, a known inhibitor of cytochrome P450 2D6, the pharmacodynamic effects of oxycodone were unchanged.

Pharmacodynamics

A single-dose, double-blind, placebo- and dose-controlled study was conducted using Oxycodone HCl Controlled-Release Tablets (10, 20, and 30 mg) in an analgesic pain model involving 182 patients with moderate to severe pain.  Twenty and 30 mg of Oxycodone HCl Controlled-Release Tablets were superior in reducing pain compared with placebo, and this difference was statistically significant.  The onset of analgesic action with Oxycodone HCl Controlled-Release Tablets occurred within 1 hour in most patients following oral administration.

Clinical Trials

A double-blind placebo-controlled, fixed-dose, parallel group, two-week study was conducted in 133 patients with chronic, moderate to severe pain, who were judged as having inadequate pain control with their current therapy.  In this study, 20 mg Oxycodone HCl Controlled-Release Tablets q12h but not 10 mg Oxycodone HCl Controlled-Release Tablets q12h decreased pain compared with placebo, and this difference was statistically significant.

Indications and Usage for Oxycodone Extended-Release Tablets

Oxycodone HCl Controlled-Release Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time.

Oxycodone HCl Controlled-Release Tablets are NOT intended for use as a prn analgesic.

Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for Health Care Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society.

Oxycodone HCl Controlled-Release Tablets are not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. Oxycodone HCl Controlled-Release Tablets are only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time.  Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate.  (See American Pain Society guidelines.)

Contraindications

Oxycodone HCl Controlled-Release Tablets are contraindicated in patients with known hypersensitivity to oxycodone, or in any situation where opioids are contraindicated.  This includes patients with significant respiratory depression (in unmonitored settings or the absence of resuscitative equipment), and patients with acute or severe bronchial asthma or hypercarbia.  Oxycodone HCl Controlled-Release Tablets are contraindicated in any patient who has or is suspected of having paralytic ileus.

Warnings

OXYCODONE HCl CONTROLLED-RELEASE TABLETS ARE TO BE SWALLOWED WHOLE AND ARE NOT TO BE BROKEN, CHEWED, OR CRUSHED.  TAKING BROKEN, CHEWED, OR CRUSHED OXYCODONE HCl CONTROLLED-RELEASE TABLETS LEADS TO RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF OXYCODONE.

Oxycodone HCl Controlled-Release 80 mg Tablets, or a single dose greater than 40 mg, ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY.  A single dose greater than 40 mg, or total daily doses greater than 80 mg, may cause fatal respiratory depression when administered to patients who are not tolerant to the respiratory depressant effects of opioids.

Patients should be instructed against use by individuals other than the patient for whom it was prescribed, as such inappropriate use may have severe medical consequences, including death.

Misuse, Abuse and Diversion of Opioids

Oxycodone is an opioid agonist of the morphine-type.  Such drugs are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. 

Oxycodone can be abused in a manner similar to other opioid agonists, legal or illicit.  This should be considered when prescribing or dispensing Oxycodone HCl Controlled-Release Tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

Oxycodone HCl Controlled-Release Tablets have been reported as being abused by crushing, chewing, snorting, or injecting the dissolved product.  These practices will result in the uncontrolled delivery of the opioid and pose a significant risk to the abuser that could result in overdose and death (see WARNINGS and DRUG ABUSE AND ADDICTION).

Concerns about abuse, addiction, and diversion should not prevent the proper management of pain.   

Healthcare professionals should contact their State Professional Licensing Board, or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product.

Interactions with Alcohol and Drugs of Abuse

Oxycodone may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system depression.

DRUG ABUSE AND ADDICTION

Oxycodone HCl Controlled-Release Tablets contain oxycodone which is a full mu-agonist opioid with an abuse liability similar to morphine and is a Schedule II controlled substance.  Oxycodone, like morphine and other opioids used in analgesia, can be abused and is subject to criminal diversion.

Drug addiction is characterized by compulsive use, use for non-medical purposes, and continued use despite harm or risk of harm.  There is a potential for drug addiction to develop following exposure to opioids, including oxycodone.  Drug addiction is a treatable disease, utilizing a multi-disciplinary approach, but relapse is common. 

“Drug-seeking” behavior is very common in addicts and drug abusers.  Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s).  “Doctor shopping” to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction. 

Abuse and addiction are separate and distinct from physical dependence and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts.  In addition, abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Oxycodone HCl Controlled-Release Tablets, like other opioids, have been diverted for non-medical use.  Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised. 

Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs. 

Oxycodone HCl Controlled-Release Tablets consist of a dual-polymer matrix, intended for oral use only.  Abuse of the crushed tablet poses a hazard of overdose and death.  This risk is increased with concurrent abuse of alcohol and other substances.  With parenteral abuse, the tablet excipients, especially talc, can be expected to result in local tissue necrosis, infection, pulmonary granulomas, and increased risk of endocarditis and valvular heart injury.  Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.

Respiratory Depression

Respiratory depression is the chief hazard from oxycodone, the active ingredient in Oxycodone HCl Controlled-Release Tablets, as with all opioid agonists.  Respiratory depression is a particular problem in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other agents that depress respiration. 

Oxycodone should be used with extreme caution in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and in patients having a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression.  In such patients, even usual therapeutic doses of oxycodone may decrease respiratory drive to the point of apnea.  In these patients alternative non-opioid analgesics should be considered, and opioids should be employed only under careful medical supervision at the lowest effective dose.

Head Injury

The respiratory depressant effects of opioids include carbon dioxide retention and secondary elevation of cerebrospinal fluid pressure, and may be markedly exaggerated in the presence of head injury, intracranial lesions, or other sources of pre-existing increased intracranial pressure.  Oxycodone produces effects on pupillary response and consciousness which may obscure neurologic signs of further increases in intracranial pressure in patients with head injuries.

Hypotensive Effect

Oxycodone HCl Controlled-Release Tablets may cause severe hypotension.  There is an added risk to individuals whose ability to maintain blood pressure has been compromised by a depleted blood volume, or after concurrent administration with drugs such as phenothiazines or other agents which compromise vasomotor tone.  Oxycodone may produce orthostatic hypotension in ambulatory patients. Oxycodone, like all opioid analgesics of the morphine-type, should be administered with caution to patients in circulatory shock, since vasodilation produced by the drug may further reduce cardiac output and blood pressure.

Precautions

General

Opioid analgesics have a narrow therapeutic index in certain patient populations, especially when combined with CNS depressant drugs, and should be reserved for cases where the benefits of opioid analgesia outweigh the known risks of respiratory depression, altered mental state, and postural hypotension. 

Use of Oxycodone HCl Controlled-Release Tablets is associated with increased potential risks and should be used only with caution in the following conditions: acute alcoholism; adrenocortical insufficiency (e.g., Addison's disease); CNS depression or coma; delirium tremens; debilitated patients; kyphoscoliosis associated with respiratory depression; myxedema or hypothyroidism; prostatic hypertrophy or urethral stricture; severe impairment of hepatic, pulmonary or renal function; and toxic psychosis. 

The administration of oxycodone may obscure the diagnosis or clinical course in patients with acute abdominal conditions.  Oxycodone may aggravate convulsions in patients with convulsive disorders, and all opioids may induce or aggravate seizures in some clinical settings.

Interactions with other CNS Depressants

Oxycodone HCl Controlled-Release Tablets should be used with caution and started in a reduced dosage (1/3 to 1/2 of the usual dosage) in patients who are concurrently receiving other central nervous system depressants including sedatives or hypnotics, general anesthetics, phenothiazines, other tranquilizers, and alcohol.  Interactive effects resulting in respiratory depression, hypotension, profound sedation, or coma may result if these drugs are taken in combination with the usual doses of Oxycodone HCl Controlled-Release Tablets.

Interactions with Mixed Agonist/Antagonist Opioid Analgesics

Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, and butorphanol) should be administered with caution to a patient who has received or is receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone. In this situation, mixed agonist/antagonist analgesics may reduce the analgesic effect of oxycodone and/or may precipitate withdrawal symptoms in these patients.

Ambulatory Surgery and Postoperative Use

Oxycodone HCl Controlled-Release Tablets are not indicated for pre-emptive analgesia (administration pre-operatively for the management of postoperative pain).

Oxycodone HCl Controlled-Release Tablets are not indicated for pain in the immediate postoperative period (the first 12 to 24 hours following surgery) for patients not previously taking the drug, because its safety in this setting has not been established.

Oxycodone HCl Controlled-Release Tablets are not indicated for pain in the postoperative period if the pain is mild or not expected to persist for an extended period of time. 

Oxycodone HCl Controlled-Release Tablets are only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time.  Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate (See American Pain Society guidelines). 

Patients who are already receiving Oxycodone HCl Controlled-Release Tablets as part of ongoing analgesic therapy may be safely continued on the drug if appropriate dosage adjustments are made considering the procedure, other drugs given, and the temporary changes in physiology caused by the surgical intervention (seeDOSAGE AND ADMINISTRATION). 

Oxycodone HCl Controlled-Release Tablets and other morphine-like opioids have been shown to decrease bowel motility.  Ileus is a common postoperative complication, especially after intra-abdominal surgery with opioid analgesia.  Caution should be taken to monitor for decreased bowel motility in postoperative patients receiving opioids.  Standard supportive therapy should be implemented.

Use in Pancreatic/Biliary Tract Disease

Oxycodone may cause spasm of the sphincter of Oddi and should be used with caution in patients with biliary tract disease, including acute pancreatitis. Opioids like oxycodone may cause increases in the serum amylase level.

Tolerance and Physical Dependence

Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Physical dependence is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist. Physical dependence and tolerance are not unusual during chronic opioid therapy.

The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other symptoms also may develop, including: irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.

In general, opioids should not be abruptly discontinued (see DOSAGE AND ADMINISTRATION: Cessation of Therapy).

Information for Patients/Caregivers

If clinically advisable, patients receiving Oxycodone HCl Controlled-Release Tablets or their caregivers should be given the following information by the physician, nurse, pharmacist, or caregiver:

1. Patients should be aware that Oxycodone HCl Controlled-Release Tablets contain oxycodone, which is a morphine-like substance.


2. Patients should be advised that Oxycodone HCl Controlled-Release Tablets were designed to work properly only if swallowed whole.  Oxycodone HCl Controlled-Release Tablets will release all their contents at once if broken, chewed, or crushed, resulting in a risk of fatal overdose.


3. Patients should be advised to report episodes of breakthrough pain and adverse experiences occurring during therapy.  Individualization of dosage is essential to make optimal use of this medication.


4. Patients should be advised not to adjust the dose of Oxycodone HCl Controlled-Release Tablets without consulting the prescribing professional.


5. Patients should be advised that Oxycodone HCl Controlled-Release Tablets may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating heavy machinery).


6. Patients should not combine Oxycodone HCl Controlled-Release Tablets with alcohol or other central nervous system depressants (sleep aids, tranquilizers) except by the orders of the prescribing physician, because dangerous additive effects may occur, resulting in serious injury or death.


7. Women of childbearing potential who become, or are planning to become, pregnant should be advised to consult their physician regarding the effects of analgesics and other drug use during pregnancy on themselves and their unborn child.


8. Patients should be advised that Oxycodone HCl Controlled-Release Tablets are a potential drug of abuse.  They should protect it from theft, and it should never be given to anyone other than the individual for whom it was prescribed.


9. Patients should be advised that they may pass empty matrix "ghosts" (tablets) via colostomy or in the stool, and that this is of no concern since the active medication has already been absorbed.


10. Patients should be advised that if they have been receiving treatment with Oxycodone HCl Controlled-Release Tablets for more than a few weeks and cessation of therapy is indicated, it may be appropriate to taper the Oxycodone HCl Controlled-Release Tablets dose, rather than abruptly discontinue it, due to the risk of precipitating withdrawal symptoms.  Their physician can provide a dose schedule to accomplish a gradual discontinuation of the medication.


11. Patients should be instructed to keep Oxycodone HCl Controlled-Release Tablets in a secure place out of the reach of children.  When Oxycodone HCl Controlled-Release Tablets are no longer needed, the unused tablets should be destroyed by flushing down the toilet.

Use in Drug and Alcohol Addiction

Oxycodone HCl Controlled-Release Tablets are an opioid with no approved use in the management of addictive disorders.  Its proper usage in individuals with drug or alcohol dependence, either active or in remission, is for the management of pain requiring opioid analgesia.

Drug-Drug Interactions

Opioid analgesics, including Oxycodone HCl Controlled-Release Tablets, may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.

Inhibitors of CYP3A4:

Since the CYP3A4 isoenzyme plays a major role in the metabolism of oxycodone, co-administration of drugs that inhibit CYP3A4 activity, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may cause decreased clearance of oxycodone which could lead to an increase in oxycodone plasma concentrations.  Although clinical studies have not been conducted, the expected clinical results would be increased or prolonged opioid effects.  If co-administration with Oxycodone HCl Controlled-Release Tablets is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP450 inhibitors.  These patients should be evaluated at frequent intervals and dose adjustments considered until stable drug effects are achieved.

Inducers of CYP3A4:

Although clinical studies have not been conducted, CYP450 inducers, such as rifampin, carbamazepine, and phenytoin, may induce the metabolism of oxycodone and, therefore, may cause increased clearance of the drug, which could lead to a decrease in oxycodone plasma concentrations, lack of efficacy, or, possibly, development of abstinence syndrome in a patient who had developed physical dependence to oxycodone.  If co-administration with Oxycodone HCl Controlled-Release Tablets is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP450 inducers.  These patients should be evaluated at frequent intervals and dose adjustments considered until stable drug effects are achieved.

Inhibitors of CYP2D6:

Oxycodone is metabolized in part to oxymorphone via cytochrome P450 2D6.  While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs including amiodarone and quinidine as well as polycyclic antidepressants), such blockade has not yet been shown to be of clinical significance with this agent.  Clinicians should be aware of this possible interaction, however.

Use with CNS Depressants

Oxycodone HCl Controlled-Release Tablets, like all opioid analgesics, should be started at 1/3 to 1/2 of the usual dosage in patients who are concurrently receiving other central nervous system depressants including sedatives or hypnotics, general anesthetics, phenothiazines, centrally acting anti-emetics, tranquilizers, and alcohol because respiratory depression, hypotension, and profound sedation or coma may result.  No specific interaction between oxycodone and monoamine oxidase inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies of oxycodone to evaluate its carcinogenic potential have not been conducted.

Oxycodone was not mutagenic in the following assays: Ames Salmonella and E. coli test with and without metabolic activation at doses of up to 5000 µg, chromosomal aberration test in human lymphocytes in the absence of metabolic activation at doses of up to 1500 µg/mL and with activation 48 hours after exposure at doses of up to 5000 µg/mL, and in the in vivo bone marrow micronucleus test in mice (at plasma levels of up to 48 µg/mL).  Oxycodone was clastogenic in the human lymphocyte chromosomal assay in the presence of metabolic activation in the human chromosomal aberration test (at greater than or equal to 1250 µg/mL) at 24 but not 48 hours of exposure and in the mouse lymphoma assay at doses of 50 µg/mL or greater with metabolic activation and at 400 µg/mL or greater without metabolic activation.

Pregnancy

Teratogenic Effects - Category B: Reproduction studies have been performed in rats and rabbits by oral administration at doses up to 8 mg/kg and 125 mg/kg, respectively.  These doses are 3 and 46 times a human dose of 160 mg/day, based on mg/kg basis.  The results did not reveal evidence of harm to the fetus due to oxycodone.  There are, however, no adequate and well-controlled studies in pregnant women.  Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Labor and Delivery

Oxycodone HCl Controlled-Release Tablets are not recommended for use in women during and immediately prior to labor and delivery because oral opioids may cause respiratory depression in the newborn.  Neonates whose mothers have been taking oxycodone chronically may exhibit respiratory depression and/or withdrawal symptoms, either at birth and/or in the nursery.

Nursing Mothers

Low concentrations of oxycodone have been detected in breast milk.  Withdrawal symptoms can occur in breast-feeding infants when maternal administration of an opioid analgesic is stopped.  Ordinarily, nursing should not be undertaken while a patient is receiving Oxycodone HCl Controlled-Release Tablets because of the possibility of sedation and/or respiratory depression in the infant.

Pediatric Use

Safety and effectiveness of Oxycodone HCl Controlled-Release Tablets have not been established in pediatric patients below the age of 18.  It must be remembered that Oxycodone HCl Controlled-Release Tablets cannot be crushed or divided for administration.

Geriatric Use

In controlled pharmacokinetic studies in elderly subjects (greater than 65 years) the clearance of oxycodone appeared to be slightly reduced.  Compared to young adults, the plasma concentrations of oxycodone were increased approximately 15% (see PHARMACOKINETICS AND METABOLISM). Of the total number of subjects (445) in clinical studies of Oxycodone HCl Controlled-Release Tablets, 148 (33.3%) were age 65 and older (including those age 75 and older) while 40 (9.0%) were age 75 and older.  In clinical trials with appropriate initiation of therapy and dose titration, no untoward or unexpected side effects were seen in the elderly patients who received Oxycodone HCl Controlled-Release Tablets.  Thus, the usual doses and dosing intervals are appropriate for these patients.  As with all opioids, the starting dose should be reduced to 1/3 to 1/2 of the usual dosage in debilitated, non-tolerant patients.  Respiratory depression is the chief hazard in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other agents that depress respiration.

Laboratory Monitoring

Due to the broad range of plasma concentrations seen in clinical populations, the varying degrees of pain, and the development of tolerance, plasma oxycodone measurements are usually not helpful in clinical management. Plasma concentrations of the active drug substance may be of value in selected, unusual or complex cases.

Hepatic Impairment

A study of Oxycodone HCl Controlled-Release Tablets in patients with hepatic impairment indicates greater plasma concentrations than those with normal function.  The initiation of therapy at 1/3 to 1/2 the usual doses and careful dose titration is warranted.

Renal Impairment

In patients with renal impairment, as evidenced by decreased creatinine clearance (<60 mL/min), the concentrations of oxycodone in the plasma are approximately 50% higher than in subjects with normal renal function. Dose initiation should follow a conservative approach. Dosages should be adjusted according to the clinical situation.

Gender Differences

In pharmacokinetic studies, opioid-naive females demonstrate up to 25% higher average plasm